Skip to main navigation
Innate Pharma logo
  • Overview
  • News & Events
    • Press Releases
    • Events
  • Regulated Information
    • Financial Reports
    • SEC Filings
    • Corporate Social Responsibility
    • General Shareholders' Meeting
    • Number of Shares and Voting Rights
    • Articles of Association
    • Corporate Transparency
    • Share Repurchase: liquidity agreement
    • Declaration by the Management Board and the Supervisory Board members
    • Prospectus Related to Public Offering
    • Appraiser Reports
  • Share Information
    • Share Information
    • Stock Quote & Chart
    • Historic Price Lookup
    • Investment Calculator
    • Analyst Coverage
  • Key Documents
  • Corporate Governance
    • Governance Overview
    • Committee Composition
  • Investor Relations

Key Documents

Key Documents

Documents
Corporate Presentation | February 2021 3.3 MB
Form 20-F 2.5 MB
Document d’Enregistrement Universel for the year 2019 (April 2020) 7.9 MB
Latest Financial Results
Feb 24, 2021
Number of shares and voting rights of Innate Pharma as of February 1, 2021
Nov 17, 2020
Innate Pharma reports third quarter 2020 financial results and business update
Sep 08, 2020
Innate Pharma reports first half 2020 financial results and business update
May 12, 2020
Innate Pharma First Quarter 2020 Report
Mar 10, 2020
Innate Pharma Reports Full Year 2019 Financial Results and Business Update
Nov 13, 2019
Innate Pharma third quarter 2019 report
Sep 13, 2019
Innate Pharma reports first half 2019 financial results and business update
May 15, 2019
Innate Pharma First Quarter 2019 Report
Mar 20, 2019
2018 financial results and business update: landmark deal with AstraZeneca to support transition into a fully integrated oncology-focused biotech, strong clinical progress in lead assets
Nov 15, 2018
Third quarter 2018 report
  • Print
  • Email Alerts
  • RSS Feeds
  • Search

© 2021 Innate Pharma